Chemotherapy for epithelial ovarian cancer: An update

Current Obstetrics and Gynaecology

Volumn 7, Issue 1, 1997, Pages 50-60

  Rea, D ^a   Poole, C ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; MARIMASTAT; PACLITAXEL; TOPOTECAN;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GENE THERAPY; HUMAN; LEUKOPENIA; NAUSEA; OVARY CANCER; REVIEW; VOMITING;

EID: 0030940749     PISSN: 09575847     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0957-5847(97)80010-8     Document Type: Article

References (20)

1. Poole C, Kerr D. The clinical evaluation of novel chemotherapeutic agents. In: Kerr D, Workman P (eds). New molecular targets for cancer chemotherapy. Boca Raton, Anne Arbor: CRC Press. 1994: 195-212
2. Calman. The provision of cancer care in the UK: report by an expert working party. Department of Health 1995
3. Bolis G, Columbo N, Favelli G et al. Randomised multicentre clinical trial in stage I epithelial ovarian cancer. Proc Am Soc Clin Oncol 1992; 11: 225
4. Kaern J, Trope C. Adjuvant treatment of stage I ovarian cancer: how can we prevent overtreatment? Proc ASCO 1992; 11: 225
5. Omura G, Bundy B, Berek J et al. Randomised trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma. J Clin Oncol 1989; 7: 457-465
6. Warwick J, Kehoe S, Earl H. Long term follow-up of patients with ovarian cancer involved in clinical trials - important prognostic features. Br J Cancer 1995; 72(6): 1513-1517
7. Griffiths R, Cummins C, Kirk A et al. Cancer and Health: joint report of the West Midlands Regional Director of Public Health and the West Midlands Cancer Registry. West Midlands Regional Health Authority 1995
8. Hunter R, Alexander N, Soutter W. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent prognostic factor? Am J Obstet Gynecol 1992; 166: 504-511
9. Hacker N, Berek J, Lagasse L et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983; 61: 413-420
10. Hoskins W, Bundy B, Thigpen J et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small volume stage III epithelial ovarian cancer, a Gynaecologic Oncology Group Study. Gynae Oncol 1992; 47: 159-166
11. Heintz A, van Oosterom A, Trimbos J. The treatment of advanced ovarian carcinoma (1) clinical variables associated with prognosis. Gynecol Oncol 1988; 30: 347-358
12. Webb M. Cytoreduction in ovarian cancer: achievability and results. In: Burghardt E, Monagham J (eds). Operative treatment of ovarian cancer. London: Baillière Tindall. 1989: 83-94
13. Van der Burg M, Van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995; 332: 629-634
14. Redman C, Warwick J, Leusley D et al. Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol 1994; 101: 142-146
15. Young R. Chemotherapy of ovarian cancer: past and present. Sem One 1975; 2: 267-276
16. Masterson J. Management of ovarian cancer: surgery, irradiation, and chemotherapy. Am J Obstet Gynecol 1967; 98: 374-386
17. Lambert H, Berry R. High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group. Br Med J 1985; 290: 889-892
18. Hakes T, Hoskins W, Jones W et al. Randomised prospective trial of 5 versus 10 cycles of cyclophosphamide doxorubicin, and cisplatin (CAP) in stage III and IV ovarian cancer. Proc ASCO 1990; 9: 156
19. Calvert A, Newell D, Gumbrell L et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 17(11): 1748-1756
20. Rankin E, Mill L, Kaye S et al. A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. Br J Cancer 1992; 65: 275-281